Stockscreener 앱 받기
7.31
0.14%
0.010
시간 외 거래:
7.31
전일 마감가:
$7.30
열려 있는:
$7.3
하루 거래량:
81,420
Relative Volume:
0.55
시가총액:
$53.36M
수익:
$1.98M
순이익/손실:
$-9.63M
주가수익비율:
-4.1409
EPS:
-1.7653
순현금흐름:
$-9.76M
1주 성능:
-9.19%
1개월 성능:
-21.99%
6개월 성능:
+153.82%
1년 성능:
+98.64%
1일 변동 폭
$7.19
$7.70
1주일 범위
$7.19
$8.4999
52주 변동 폭
$2.52
$12.37
Lipocine Inc Stock (LPCN) Company Profile
명칭
Lipocine Inc
전화
801 994 7383
주소
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
7.31 | 53.29M | 1.98M | -9.63M | -9.76M | -1.7653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-06-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-11 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 재개 | H.C. Wainwright | Buy |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
| 2015-06-23 | 개시 | Canaccord Genuity | Buy |
모두보기
Lipocine Inc 주식(LPCN)의 최신 뉴스
Lipocine Announces 2025 Financial Results and Progress on Postpartum Depression, Epilepsy, and Obesity Drug Pipeline - Minichart
Lipocine Inc. 2025 Annual Report: Innovative Oral Drug Delivery, CNS & Metabolic Pipeline, and R&D Highlights - Minichart
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PR Newswire
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Lipocine 2025 Financial Results: Q4 & Annual PerformanceNews and Statistics - IndexBox
Lipocine: Fourth Quarter Financial Results Overview - Bitget
Lipocine: Q4 Earnings Snapshot - Barchart
Lipocine (NASDAQ: LPCN) 2025 revenue falls to $2M with $9.6M loss - Stock Titan
Lipocine 10-K: Revenue $2.0M, EPS (Basic) $(1.77) - TradingView
Lipocine Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Is Lipocine Inc affected by consumer sentiment2026 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
AI Stocks: Will Lipocine Inc benefit from rate cuts2025 Support & Resistance & Daily Profit Maximizing Tips - baoquankhu1.vn
Lipocine Stock Quote, Share Price, News and Analysis - Longbridge
Lipocine Files Prospectus to Enable $50M Stock Offering - The Globe and Mail
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (LPCN) establishes $50M at-the-market common stock sales plan - Stock Titan
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - Nasdaq
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Lipocine Files For Common Stock Offering Of Up To $50 MillionSEC Filing - TradingView
LivePerson (NASDAQ: LPCN) increases ATM sales capacity to $50M - Stock Titan
Lipocine (LPCN) Jumps 5.5%: Does the Stock Have More Room to Grow? - Bitget
ETF Watch: Is Lipocine Inc a turnaround storyTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Can Lipocine Inc. stock beat market expectations this quarterTreasury Yields & Short-Term High Return Ideas - mfd.ru
Lipocine completes patient visits in phase 3 trial for PPD treatment - Investing.com Australia
Lipocine completes patient visits in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Trial for Postpartum Depression - TipRanks
Lipocine (NASDAQ: LPCN) files updated corporate investor presentation - Stock Titan
Is Lipocine Inc. stock a buy on dips2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Is Lipocine Inc. a potential multi baggerMarket Volume Summary & Low Drawdown Momentum Ideas - mfd.ru
Lipocine Announces Late Breaking Oral Presentation of Data from - GuruFocus
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Finviz
Does Lipocine Inc. stock have upside surprise potential2025 Stock Rankings & Long Hold Capital Preservation Tips - mfd.ru
Why Lipocine Inc. stock is favored by top institutionsJuly 2025 WrapUp & Smart Allocation Stock Reports - mfd.ru
S P Trends: Does Lipocine Inc offer margin of safetyMarket Activity Summary & Short-Term High Return Ideas - baoquankhu1.vn
Lipocine Announces Positive Interim Results for PPD Trial - MSN
Lipocine (LPCN) Price Target Increased by 58.18% to 11.09 - Nasdaq
Market Moves: Can Lipocine Inc ride the EV waveJuly 2025 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
EV Market: Is Lipocine Inc a cyclical or defensive stockPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com India
Lipocine completes enrollment in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug - TipRanks
Lipocine Inc Completes Enrollment in Phase 3 Trial for PPD Treatment - TradingView
Lipocine completes enrollment in phase 3 trial for PPD treatment - Investing.com
At-home postpartum depression drug from Lipocine tested in 90 women - Stock Titan
CEO Moves: Can Lipocine Inc ride the EV waveJuly 2025 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Performance Recap: What is TREEs TAM Total Addressable MarketWeekly Market Outlook & Weekly High Return Opportunities - baoquankhu1.vn
LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN
Lipocine Inc (LPCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):